- Home
- PPHC vs NMRA Comparison
PPHC vs NMRA Comparison
Compare PPHC & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Company Overview
Basic Information| Metric | PPHC | NMRA |
|---|---|---|
| Founded | N/A | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | |
| Sector | | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 305.8M | 302.0M |
| IPO Year | 2025 | 2023 |
Fundamental Metrics
Financial Performance| Metric | PPHC | NMRA |
|---|---|---|
| Price | $10.65 | $1.31 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 87.9K | ★ 665.2K |
| Earning Date | N/A | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.23 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $186,541,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 24.72 | N/A |
| 52 Week Low | $7.01 | $0.83 |
| 52 Week High | $15.15 | $3.65 |
Technical Indicators
Market Signals| Indicator | PPHC | NMRA |
|---|---|---|
| Relative Strength Index (RSI) | 58.84 | 38.09 |
| Support Level | $11.34 | $0.83 |
| Resistance Level | $11.80 | $1.77 |
| Average True Range (ATR) | 0.80 | 0.11 |
| MACD | 0.02 | -0.02 |
| Stochastic Oscillator | 86.13 | 11.25 |
Price Performance
Historical ComparisonAbout PPHC Public Policy Holding Company Inc. Common Stock
Public Policy Holding Co Inc operates as a advisory firm. The company also operates a portfolio of independent firms that offer public affairs, crisis management, lobbying, and advocacy services on behalf of the corporate, trade association, and non-profit client organisations. Its business comprises of three reporting segments - Government Relations Consulting, Corporate Communications & Public Affairs Consulting and Compliance and Insights Services.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.